News Column

Study Results from Seoul National University Update Understanding of Stem Cells (Umbilical-cord-blood-derived mesenchymal stem cells seeded onto...

August 18, 2014



Study Results from Seoul National University Update Understanding of Stem Cells (Umbilical-cord-blood-derived mesenchymal stem cells seeded onto fibronectin-immobilized polycaprolactone nanofiber improve cardiac function)

By a News Reporter-Staff News Editor at Cardiovascular Week -- Investigators publish new report on Stem Cell Research. According to news reporting originating in Seoul, South Korea, by NewsRx journalists, research stated, "Stem cells seeded onto biofunctional materials have greater potency for therapeutic applications. We investigated whether umbilical-cord-blood-derived mesenchymal stem cell (UCB-MSC)-seeded fibronectin (FN)-immobilized polycaprolactone (PCL) nanofibers could improve cardiac function and inhibit left ventricle (LV) remodeling in a rat model of myocardial infarction (MI)."

The news reporters obtained a quote from the research from Seoul National University, "Aligned nanofibers were uniformly coated with poly(glycidyl methacrylate) by initiated chemical vapor deposition followed by covalent immobilization of FN proteins. The degree of cell elongation and adhesion efficacy were improved by FN immobilization. Furthermore, genes related to angiogenesis and mesenchymal differentiations were up-regulated in the FN-immobilized PCL nanofibers in comparison to control PCL nanofibers in vitro. 4 weeks after the transplantation in the rat MI model, the echocardiogram showed that the UCB-MSC-seeded FN-immobilized PCL nanofiber group increased LV ejection fraction and fraction shortening as compared to the non-treated control and acellular FN-immobilized PCL nanofiber groups. Histological analysis indicated that the implantation of UCB-MSCs with FN-immobilized PCL nanofibers induced a decrease in MI size and fibrosis, and an increase in scar thickness."

According to the news reporters, the research concluded: "This study indicates that FN-immobilized biofunctional PCL nanofibers could be an effective carrier for UCB-MSC transplantation for the treatment of MI."

For more information on this research see: Umbilical-cord-blood-derived mesenchymal stem cells seeded onto fibronectin-immobilized polycaprolactone nanofiber improve cardiac function. Acta Biomaterialia, 2014;10(7):3007-17. (Elsevier - www.elsevier.com; Acta Biomaterialia - www.elsevier.com/wps/product/cws_home/702994)

Our news correspondents report that additional information may be obtained by contacting B.J. Kang, Dept. of Veterinary Biochemistry, BK21 Plus and Research Institute of Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, South Korea. Additional authors for this research include H. Kim, S.K. Lee, J. Kim, Y. Shen, S. Jung, K.S. Kang, S.G. Im, S.Y. Lee, M. Choi, N.S. Hwang and J.Y Cho (see also Stem Cell Research).

Keywords for this news article include: Asia, Seoul, Nanofiber, Cardiology, South Korea, Fibronectins, Nanotechnology, Serum Globulins, Stem Cell Research, Emerging Technologies, Membrane Glycoproteins, Mesenchymal Stem Cells, Extracellular Matrix Proteins.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cardiovascular Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters